Tradestie Institutional Equity Comparison Engine

ATHA vs IRD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ATHA Overall Edge

ATHA Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Athira Pharma, Inc. Common Stock (ATHA) driven by superior Growth & Margin, Momentum & Technical while IRD counters with relative strength in Valuation, Options & Structure. Fundamentally, ATHA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus IRD at 12.0x Forward P/E and -777.7% operating margin (-63.1% YoY). In options structure, ATHA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IRD sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner IRD
ATHA N/M vs IRD 12.0x Fwd P/E
Growth & Margin Winner ATHA
Op Margin 0.0% vs -777.7% ยท YoY +0.0% vs -63.1%
Momentum & Technical Winner ATHA
1Y +12.5% vs +113.0% ยท 52W Pos 80% vs 42%
Options & Structure Winner IRD
UNCLASSIFIED (N/A IV) vs BREAKDOWN (12th %ile IV)
ATHA NASDAQ
Athira Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.75
-6.12% 1D
Market Cap $26.6M
1M Return +73.75%
1Y Return +12.5%
Forward P/E N/M
Unified AI Score
56.2 / 100 HOLD
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
IRD NASDAQ
Opus Genetics, Inc. Common Stock
Pharmaceutical Preparations
$3.94
-1.01% 1D
Market Cap $392.4M
1M Return +2.6%
1Y Return +112.97%
Forward P/E 12.0x
Unified AI Score
39.9 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ATHA +12.5% IRD +112.97% Spread: +39.45 pp (ATHA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ATHA TTM Op. Margin: 0.0% IRD TTM Op. Margin: -777.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATHA vs IRD. Trailing 12-month operating profitability (ATHA 0.0% vs IRD -777.7%) and valuation multiples (ATHA N/M vs IRD 12.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ATHA (5) vs IRD (4)
Institutional Metric ATHA IRD Criterion Row Winner
Market Capitalization Scale $26.6M $392.4M Larger Scale IRD
Trailing P/E Ratio Valuation N/M 12.0x Lower Multiple IRD
Forward P/E Ratio Valuation N/M 12.0x Lower Multiple IRD
Revenue Growth (YoY) Growth +0.0% -63.1% Higher Growth ATHA
Operating Margin (TTM) Profitability 0.0% -777.7% Higher Margin ATHA
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -89.4% -615.6% Higher ROE ATHA
52-Week Range Position Momentum 80% ($0โ€“$8) 42% ($2โ€“$7) Stronger Trend ATHA
Beta / 30D Volatility Risk Regime 6.17ฮฒ ยท 241% Vol 1.47ฮฒ ยท 76% Vol Lower Realized Risk IRD
Unified Institutional Score Composite Signal 56.2 / 100 (HOLD) 39.9 / 100 (SELL) Higher Composite ATHA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ATHA vs IRD Buy Guide
ATHA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ATHA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IRD BREAKDOWN
47d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live IRD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ATHA nor IRD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.